| NCT05703971 | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | RECRUITING | PHASE1, PHASE2 | 2024-05-09 | 2027-08 | 2026-02 |
| NCT05062980 | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | TERMINATED | PHASE1, PHASE2 | 2022-03-30 | 2025-02-03 | 2025-02-03 |
| NCT04486833 | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | RECRUITING | PHASE1, PHASE2 | 2021-09-03 | 2029-03 | 2028-03 |
| NCT01455389 | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | TERMINATED | PHASE1, PHASE2 | 2014-02 | 2020-09-28 | 2016-10-27 |